Allarity Therapeutics Expanded Research Laboratory Capabilities
The company added proteomics and cell line research to its in-house diagnostic and clinical testing operations.
Updated on Sept. 28, 2026 in Biotech
Live Poll
Do you believe internal laboratory expansion by pharmaceutical companies benefits patients in the long term?
Allarity Therapeutics has enhanced its internal laboratory in Tarpon Springs, Florida, to include new proteomics and cell line research capabilities. The facility now utilizes an nCounter Pro instrument to conduct advanced molecular studies alongside its existing transcriptomics and clinical testing services.
Why it matters
These expanded capabilities are designed to deepen the company's internal research into the mechanism of action of its lead drug candidate, stenoparib. By integrating these new tools, the firm also aims to provide a wider array of research services to external partners.
The laboratory now utilizes an nCounter Pro instrument that measures approximately 300 protein targets via a dedicated diagnostic panel. These new tools augment previous capabilities focused on transcriptomics and CLIA-certified clinical testing.
The players
Allarity Therapeutics
This is a biotech firm that focuses on developing personalized cancer treatments and holds exclusive global rights to the dual PARP and WNT pathway inhibitor stenoparib.
The details
The laboratory integration supports the development of stenoparib, a dual PARP and WNT pathway inhibitor for which the firm holds exclusive global rights. Management expects that these upgrades will generate operational cost efficiencies while enhancing the firm's data generation regarding molecular insights.
Timeline
September 28, 2026: Allarity Therapeutics announced the expansion of its laboratory capabilities.
The Tech Race
This move reflects a broader industry shift toward internalizing multi-omic diagnostic capabilities to accelerate drug discovery pipelines. By adopting the nCounter Pro instrument, the firm is transitioning away from reliance on external service providers to maintain tighter control over molecular research data.
This development serves as an internal operational upgrade rather than a change in current clinical product availability for patients. Investors and partners may see future improvements in research efficiency as the company leverages these tools to study its drug portfolio.
The takeaway
The expansion demonstrates a strategic push by the company to optimize its internal research processes for stenoparib development. Integrating proteomics into existing workflows may allow the firm to reduce long-term diagnostic service costs.
Further reading
For more information on the evolving laboratory landscape, visit the Biotech section.
Live Poll
Do you believe internal laboratory expansion by pharmaceutical companies benefits patients in the long term?
